Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Freiburg, May 7th, 2025

(SeaPRwire) – Freiburg, May 7, 2025 Study results show that norucholic acid (NCA) is superior to placebo in terms of the co-primary endpoint. There are currently no drugs approved to treat primary sclerosing cholangitis. Results from the 96-week analysis of the NUC-5 trial will be presented at the 2025 EASL Congress in Amsterdam. Dr.

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis – Thailand Tribune

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical ...